RetinAI Medical AG, which creates advanced clinical and imaging data management and analytics software using artificial intelligence (AI) for ophthalmology, partnered with Boehringer Ingelheim.
The company aims to improve patient outcomes in geographic atrophy (GA) by combining its Discovery RetinAI platform and AI tools with Boehringer Ingelheim’s research on retinal diseases.
GA is a progressive and advanced form of age-related macular degeneration and a leading cause of total vision loss, estimated to affect approximately 5 million people worldwide. As the population ages, the prevalence of this disease is expected to increase. Losing sight is traumatic and has a permanent impact on many aspects of life.
RetinAI’s AI tool for identifying new biomarkers will analyze Boehringer Ingelheim’s imaging dataset from clinical studies and real-world evidence to identify additional new biomarkers and predictors of disease progression. This integration of advanced digital technology and AI can help accelerate the development of new treatments and enable earlier and more precise diagnoses that contribute to Boehringer Ingelheim’s vision to prevent vision loss and blindness caused by retinal disease.
“RetinAI is excited to begin this very important collaboration with Boehringer Ingelheim, a leader in the development and application of innovative and more accurate digital technology treatments in retinal diseases,” said Carlos Ciller, CEO of RetinAI.
“Our new Discovery platform and AI tools at GA accelerate research and provide powerful disease insights. We are confident that this collaboration with Boehringer Ingelheim can pave the way towards new, more patient-tailored treatments to change the lives of people living with retinal disease.”
About Retin AI
RetinAI, founded in 2017, is a Swiss company developing software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. RetinAI builds tools to collect, organize, and analyze health data from the eye, enabling healthcare professionals to make informed decisions more quickly in healthcare.
RetinAI partners with ophthalmologists to help accelerate data analysis and more effectively achieve target-based research for better study design, clinical studies, and research. Its data management platform and models, including AI models for prediction of geographic atrophy progression, analyze data sets at scale to gain in-depth understanding of biomarker profiles and patient subgroups or outcomes.